A phenotypic signature-based strategy that identifies tumor-specific TCR in fresh human colorectal cancers
Cancer Immunology, Immunotherapy · 13.11.2026
DOI: 10.1007/s00262-026-04634-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 13.11.2026. Verfasst von Xiya Wang und 9 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: the National Key Research and Development Program of China Grant, the National Natural Science Foundation of China, the Fundamental and Interdisciplinary Disciplines Breakthrough Plan of the Ministry of Education of China.
Abstract (Originalsprache)
Despite advances in cancer immunotherapy, solid tumors remain challenging due to antigenic heterogeneity and immunosuppressive microenvironments. T-cell receptor-engineered T cells (TCR-T) hold promises by targeting intracellular antigens, yet identifying tumor-specific TCRs is hindered by the rarity of tumor-reactive T cells. Here, we developed a phenotypic signature-based strategy to efficiently isolate tumor-specific TCRs from colorectal cancer (CRC) tumor-infiltrating lymphocytes (TILs). We leveraged the co-expression of surface markers CD39, CD103, and PD-1 to enrich CXCL13^+ CD8^+ T cells, a subset linked to tumor reactivity and improved patient survival. Single-cell RNA sequencing and flow cytometry of a small cohort CRC patients revealed that triple-positive (CD39^+CD103^+PD-1^+) CD8^+ TILs exhibited the highest CXCL13 enrichment, providing a basis for subsequent TCR clonotype identification. High-throughput TCR sequencing of the enriched cells identified dominant clonotypes, which were validated using autologous tumor organoids. A top candidate TCR (TCR-1A7) demonstrated robust tumor-specific cytotoxicity, as evidenced by upregulated activation markers (CD69, CD137), cytokine secretion (IFN-γ, granzyme B), and tumor organoid apoptosis, while sparing normal tissues. MHC blockade confirmed antigen-specific recognition. Combining phenotypic profiling, TCR screening, and organoid-based validation, this integrative approach proposes a potential framework for developing precision TCR-T therapies against solid tumors, addressing critical bottlenecks in efficacy and safety.
Förderung
- the National Key Research and Development Program of China Grant
- the National Natural Science Foundation of China
- the Fundamental and Interdisciplinary Disciplines Breakthrough Plan of the Ministry of Education of China
Zitieren
APA
Wang, X., Ji, X., Ma, L., Li, Z., Li, Y., Zhang, Q., Zhang, P., Che, X., Sun, Y., & Bai, Y. (2026). A phenotypic signature-based strategy that identifies tumor-specific TCR in fresh human colorectal cancers. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04634-2
Vancouver
Wang X, Ji X, Ma L, Li Z, Li Y, Zhang Q, et al. A phenotypic signature-based strategy that identifies tumor-specific TCR in fresh human colorectal cancers. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04634-2
BibTeX
@article{Wang2026,
author = {Wang, Xiya and Ji, Xiangwen and Ma, Lisha and Li, Zhilang and Li, Yixian and Zhang, Qianjing and Zhang, Pengchong and Che, Xuan and Sun, Yuan and Bai, Yun},
title = {A phenotypic signature-based strategy that identifies tumor-specific TCR in fresh human colorectal cancers},
journal = {Cancer Immunology, Immunotherapy},
year = {2026},
doi = {10.1007/s00262-026-04634-2}
}
EUVIMED